Lung cancer affects over 1.8 million people worldwide and is the leading cause of cancer related mortality globally. Currently, diagnosis of lung cancer involves a combination of imaging and invasive biopsies to confirm histopathology. Non-invasive diagnostic techniques under investigation include "liquid biopsies" through a simple blood draw to develop predictive and prognostic biomarkers. A better understanding of circulating tumor cell (CTC) dissemination mechanisms offers promising potential for the development of techniques to assist in the diagnosis of lung cancer. Enumeration and characterization of CTCs has the potential to act as a prognostic biomarker and to identify novel drug targets for a precision medicine approach to lung can...
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, ...
In the present study we investigated the prognostic value of Circulating Tumour Cells (CTC) and thei...
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, ...
Lung cancer affects over 1. 8 million people worldwide and is the leading cause of cancer related mo...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
The understanding of the natural history and biology of lung cancer has been enhanced by studies int...
Lung cancer affects over 1. 8 million people worldwide and is the leading cause of cancer related mo...
The prognostic significance of circulating tumor cells (CTCs) detected in patients with non-small-ce...
The prognostic significance of circulating tumor cells (CTCs) detected in patients with non-small-ce...
Introduction. We aimed to evaluate whether circulating tumor cells (CTCs) were the prognostic indica...
Purpose: To investigate the prognostic value of circulating tumor cells (CTCs) and to predict the tr...
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, ...
In the present study we investigated the prognostic value of Circulating Tumour Cells (CTC) and thei...
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, ...
Lung cancer affects over 1. 8 million people worldwide and is the leading cause of cancer related mo...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream that mig...
The understanding of the natural history and biology of lung cancer has been enhanced by studies int...
Lung cancer affects over 1. 8 million people worldwide and is the leading cause of cancer related mo...
The prognostic significance of circulating tumor cells (CTCs) detected in patients with non-small-ce...
The prognostic significance of circulating tumor cells (CTCs) detected in patients with non-small-ce...
Introduction. We aimed to evaluate whether circulating tumor cells (CTCs) were the prognostic indica...
Purpose: To investigate the prognostic value of circulating tumor cells (CTCs) and to predict the tr...
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, ...
In the present study we investigated the prognostic value of Circulating Tumour Cells (CTC) and thei...
Tumor biopsy is the gold standard for the assessment of clinical biomarkers for treatment. However, ...